Anavex Life Sciences Corp. (LON:0HFR)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 240.78M -65.8% |
| Revenue (ttm) | n/a |
| Net Income | -25.82M |
| EPS | -0.29 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,357 |
| Open | 3.490 |
| Previous Close | 3.440 |
| Day's Range | 3.480 - 3.560 |
| 52-Week Range | 2.270 - 11.635 |
| Beta | 1.14 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 25, 2026 |
About Anavex Life Sciences
Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ... [Read more]
News
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 11, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on August 11, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Announces Plans to Refresh Board to Continue Overseeing Critical Progress and Stockholder Value Creation
Nominates Two New Independent Directors, Mr. Gautam Patel and Dr. Adrian Senderowicz, Who Bring Deep, Relevant Experience in Life Sciences
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on July 31, 2026, providing details for shareholder voting and corporate governance matters.
Anavex Life Sciences Reports Preliminary Second Quarter 2026 Financial Results and Provides Business Update
NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (Anavex or the Company) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments fo...
Anavex Life Sciences Proxy statement: Proxy filing
Anavex Life Sciences filed a proxy statement on July 24, 2026, providing details for shareholder voting and corporate governance matters.
Anavex receives expected Nasdaq delinquency notification
Anavex (AVXL) Life Sciences announced it received an expected delinquency notification letter from the Listing Qualifications Department of The Nasdaq Stock Market on May 20, 2026. The Notice indicate...
Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
Anavex delays 10Q filing
The company states: “Anavex (AVXL) Life Sciences is unable to timely file its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2026 by the prescribed May…
Anavex Life Sciences names Terrie Kellmeyer interim CEO, succeeding Missling
Anavex (AVXL) Life Sciences announced that its board has appointed former senior VP of clinical development and current senior advisor Terrie Kellmeyer as interim CEO. The appointment follows the depa...
Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments...
Anavex initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw initiated coverage of Anavex (AVXL) with a Buy rating and $20 price target implying 500% upside from the current share price. The company is developing oral therapies…
Anavex Life Sciences Transcript: 25th Annual Needham Virtual Healthcare Conference
The session highlighted strong phase IIb/III results for blarcamesine in Alzheimer's, with significant cognitive and biomarker benefits, a robust safety profile, and a focus on pivotal studies for regulatory approval. Expansion into Parkinson's and rare diseases is supported by mechanistic rationale and financial stability.
Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer's Disease
Findings underpin the scientific rationale for Anavex's targeted autophagy approach with orally administered blarcamesine
Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference
NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex gives update after blarcamesine marketing authorization withdrawal
Anavex (AVXL) provided a regulatory update. Following the withdrawal of the application for the marketing authorization of blarcamesine in the EU, Anavex will continue to gather additional data and co...
Anavex Life Sciences Provides Comprehensive Regulatory Update
Dialogue continues with European Medicines Agency (EMA) to advance the development program of oral blarcamesine in early Alzheimer's disease
Anavex withdraws marketing authorization application for blarcamesine in the EU
Anavex (AVXL) announced that it has withdrawn its application for the marketing authorization of blarcamesine in the EU as an add-on therapy for the treatment of early Alzheimer’s disease in…
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease
NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...
Anavex presents new data from ANAVEX2-73-AD-004 program
Anavex (AVXL) announced new data of blarcamesine was presented at the AD/PD 2026 Conference, drawing from the ANAVEX2-73-AD-004 Phase IIb/III clinical program and its long-term open-label extension, A...
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer's Disease
New data show brain-volume preservation correlates with patient outcomes Long-term clinical data indicate 77.4 weeks (17.8 months) time saved with oral blarcamesine compared to ADNI 1 control group af...
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer's Disease
Findings underpin potential of Anavex' lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration Findings underpin potential of Anavex' lead candi...
Anavex presents treatment effects of blarcamesine in Parkinson’s model
Anavex (AVXL) Life Sciences announced new data of blarcamesine in a new Parkinson’s model of combined alpha-synuclein pathology and noradrenergic degeneration. Significant treatment effects of blarcam...
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson's Disease at AD/PD 2026 Conference
New data show that blarcamesine completely rescued impaired motor function Biomarker of nerve fiber density of dopaminergic nerve cells indicating fiber regrowth in striatum with blarcamesine New Park...
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatmen...